{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:46:25Z","timestamp":1789422385209,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011347","name":"University of Nevada, Reno","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA058687"],"award-info":[{"award-number":["R01 DA058687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA268491"],"award-info":[{"award-number":["R01 CA268491"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.rcsop.2024.100543","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:55:59Z","timestamp":1732024559000},"page":"100543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pharmaceutical industry use of key opinion leaders to market prescription opioids: A review of internal industry documents"],"prefix":"10.1016","volume":"16","author":[{"given":"Brian","family":"Gac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgosi","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Yakubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorie E.","family":"Apollonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2024.100543_bb0005","author":"ACTIQ"},{"key":"10.1016\/j.rcsop.2024.100543_bb0010","author":"Argoff"},{"key":"10.1016\/j.rcsop.2024.100543_bb0015","author":"Brookes"},{"issue":"8","key":"10.1016\/j.rcsop.2024.100543_bb0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2105\/AJPH.2022.306951","article-title":"The opioid industry documents archive: a living digital repository","volume":"112","author":"Caleb Alexander","year":"2022","journal-title":"Am J Public Health"},{"key":"10.1016\/j.rcsop.2024.100543_bb0025","author":"Candiotti"},{"key":"10.1016\/j.rcsop.2024.100543_bb0030","author":"Center for Disease Control and Prevention"},{"issue":"7","key":"10.1016\/j.rcsop.2024.100543_bb0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajhp\/zxy089","article-title":"The opioid crisis: origins, trends, policies, and the roles of pharmacists","volume":"76","author":"Chisholm-Burns","year":"2019","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.rcsop.2024.100543_bb0040","author":"Chronic Pain Scientific Advisory Board"},{"key":"10.1016\/j.rcsop.2024.100543_bb0045","series-title":"Medical Innovation: A Diffusion Study","author":"Coleman","year":"1966"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100543_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/nyas.14209","article-title":"Epidemiology of the U.S. opioid crisis: the importance of the vector","volume":"1451","author":"Compton","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rcsop.2024.100543_bb0055","author":"Cornwell"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100543_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.20529\/IJME.2019.043","article-title":"The marketing of OxyContin(R): a cautionary tale","volume":"4","author":"Egilman","year":"2019","journal-title":"Indian J Med Ethics"},{"key":"10.1016\/j.rcsop.2024.100543_bb0065","author":"Gac"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100543_bb0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2105\/AJPH.2005.066654","article-title":"\u201cthe doctors\u2019 choice is America\u2019s choice\u201d: the physician in US cigarette advertisements, 1930-1953","volume":"96","author":"Gardner","year":"2006","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100543_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280110","article-title":"Cannabis companies and the sponsorship of scientific research: a cross-sectional Canadian case study","volume":"18","author":"Grundy","year":"2023","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.rcsop.2024.100543_bb0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/00952990.2019.1618320","article-title":"Guiding industry settlements of opioid litigation","volume":"45","author":"Hodge","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"10.1016\/j.rcsop.2024.100543_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/wmh3.290","article-title":"Continuing medical education and the Marketing of Fentanyl for breakthrough pain: marketing messages in an industry-funded CME module on breakthrough pain","volume":"1","author":"Infeld","year":"2019","journal-title":"World Med Health Policy"},{"key":"10.1016\/j.rcsop.2024.100543_bb0090","author":"Janssen Pharmaceutica"},{"key":"10.1016\/j.rcsop.2024.100543_bb0095","series-title":"Duragesic Focused and Targeted Execution","author":"Janssen Pharmaceutica","year":"2004"},{"key":"10.1016\/j.rcsop.2024.100543_bb0100","author":"Janssen Pharmaceutical Inc"},{"key":"10.1016\/j.rcsop.2024.100543_bb0105","author":"Jones"},{"key":"10.1016\/j.rcsop.2024.100543_bb0110","series-title":"How the Voter Makes up his Mind in a Presidential Campaign","author":"Lazarsfeld","year":"1948"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100543_bb0115","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1186\/s12889-024-19642-z","article-title":"Evaluation of the strategies opioid manufacturers used to recruit health professionals and encourage overprescribing: an analysis of industry documents","volume":"24","author":"Lee","year":"2024","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.rcsop.2024.100543_bb0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1529-8019.2009.01240.x","article-title":"Key opinion leaders: where they come from and how that affects the drugs you prescribe","volume":"22","author":"Meffert","year":"2009","journal-title":"Dermatol Ther"},{"issue":"7658","key":"10.1016\/j.rcsop.2024.100543_bb0125","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/bmj.39575.675787.651","article-title":"Key opinion leaders: independent experts or drug representatives in disguise?","volume":"336","author":"Moynihan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rcsop.2024.100543_bb0130","author":"Neumann"},{"key":"10.1016\/j.rcsop.2024.100543_bb0135","author":"Oklahoma Opioid Litigation Documents"},{"key":"10.1016\/j.rcsop.2024.100543_bb0140","author":"Ortho McNell Janssen Pharmaceuticals Inc"},{"issue":"5","key":"10.1016\/j.rcsop.2024.100543_bb0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11916-018-0685-5","article-title":"America\u2019s opioid epidemic: a comprehensive review and look into the rising crisis","volume":"22","author":"Ostling","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.rcsop.2024.100543_bb0150","author":"Pharma Marketing Network"},{"issue":"19","key":"10.1016\/j.rcsop.2024.100543_bb0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJMp1902811","article-title":"Preying on prescribers (and their patients) - pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy","volume":"380","author":"Podolsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.rcsop.2024.100543_bb0160","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMp1614972","article-title":"Addressing the opioid epidemic - opportunities in the Postmarketing setting","volume":"376","author":"Psaty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rcsop.2024.100543_bb0165","author":"Purdue Pharma"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100543_bb0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41584-020-00539-1","article-title":"Key opinion leaders - a critical perspective","volume":"17","author":"Scher","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rcsop.2024.100543_bb0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2018.19320","article-title":"Medical Marketing in the United States, 1997-2016","volume":"321","author":"Schwartz","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.rcsop.2024.100543_bb0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1503\/cmaj.150032","article-title":"How to make opinion leaders and influence people","volume":"187","author":"Sismondo","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.rcsop.2024.100543_bb0185","author":"Spencer"},{"key":"10.1016\/j.rcsop.2024.100543_bb0190","author":"Teva"},{"key":"10.1016\/j.rcsop.2024.100543_bb0195","author":"Thomson"},{"key":"10.1016\/j.rcsop.2024.100543_bb0200","author":"United States Department of Justice"},{"key":"10.1016\/j.rcsop.2024.100543_bb0205","author":"University of California San Francisco (UCSF)"},{"issue":"2","key":"10.1016\/j.rcsop.2024.100543_bb0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"issue":"10","key":"10.1016\/j.rcsop.2024.100543_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/dtb.2020.000004","article-title":"Pharmaceutical marketing-greater than the sum of its parts?","volume":"58","author":"Wilcock","year":"2020","journal-title":"Drug Ther Bull"},{"issue":"11","key":"10.1016\/j.rcsop.2024.100543_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052636","article-title":"Industry strategies to market opioids to children and women in the USA: a content analysis of internal industry documents from 1999 to 2017 released in state of Oklahoma v. Purdue Pharma, L.P. et al","volume":"12","author":"Yakubi","year":"2022","journal-title":"BMJ Open"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276624001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T21:17:08Z","timestamp":1745011028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276624001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"alternative-id":["S2667276624001409"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100543","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical industry use of key opinion leaders to market prescription opioids: A review of internal industry documents","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2024.100543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100543"}}